Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

Ceng ChaiMing; Yan MaoLin; Shi YiHai; Guo TaiLin; Mei AiNong; Chen JianKang; Xu GuiPing; He XiaoHong

doi:10.3969/j.issn.1001-5256.2019.12.019

Volume 35 Issue 12

Dec. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(12): 2736-2740

PDF( 2278 KB)

Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

DOI: 10.3969/j.issn.1001-5256.2019.12.019

Department of Cadre Diagnosis and Treatment,Fujian Provincial Hospital

Research funding:

Received Date: 2019-09-16
Published Date: 2019-12-20

Abstract

Abstract

Objective To investigate the change in the expression of 17-β-hydroxysteroid dehydrogenase 13( HSD17 B13) and mitofusin2( MFN2) in hepatocellular carcinoma( HCC) tissue and its clinical significance,and to analyze target genes by bioinformatics methods.Methods Fifteen HCC patients who received surgical treatment in Fujian Provincial Hospital from September 2017 to March 2018 were enrolled. HCC and adjacent tissues were collected after surgery. Real-time PCR and Western blot were used to measure the change in the expression of HSD17 B13 and MFN2 in HCC and adjacent tissues,and the clinical significance of such change was analyzed. The single cell sequencing database,the GTEx database,and The Cancer Genome Atlas database were used to analyze the expression of HSD17 B13 and MFN2 in HCC tissue and different stages of HCC,as well as its correlation with overall survival of liver cancer. The correlation between the expression of HSD17 B13 and MFN2 was also analyzed. For normally distributed continuous data,the t test was used for comparison between two groups,and an analysis of variance was used for comparison between multiple groups; for non-normally distributed continuous data,the Mann-Whitney U test was used for comparison between two groups,and the Kruskal-Wallis H test was used for comparison between multiple groups. The log-rank test was used to investigate the influence of variables on survival rate,and the Kaplan-Meier method was used for plotting the survival curve. A Pearson correlation analysis was used to investigate the relationship between the two variables. Results Real-time PCR and Western blot showed that compared with the adjacent tissue,the HCC tissue had significantly downregulated expression of HSD17 B13 and MFN2( PCR: t =-2. 467 and-3. 933,P = 0. 020 and 0. 001; Western blot: t =-5. 357 and-5. 771,P = 0. 006 and0. 026). The bioinformatics analysis showed significantly downregulated expression of HSD17 B13 in HCC tissue( P < 0. 05),and the expression of HSD17 B13 decreased with the increase in the stage of HCC( F = 3. 220,P = 0. 023); low expression of HSD17 B13 was associated with poor survival( risk ratio = 0. 630,P = 0. 011); in HCC tissue,the expression of MFN2 was positively correlated with that of HSD17 B13( r = 0. 190,P < 0. 001). Conclusion There is downregulated expression of MFN2 and HSD17 B13 in liver cancer,and MFN2 and HSD17 B13 may be potential tumor suppressor genes with clinical relevance. They may be involved in biological behaviors in the development and progression of liver cancer and may become useful molecular markers for liver cancer screening,clinical classification,and prognosis evaluation and effective targets for the treatment of liver cancer.
- carcinoma,hepatocellular,
- progesterone reductase,
- mitochondrial membrane transport proteins,
- computational biology,
- genes,tumor suppressor

FullText(HTML)

References(19)

References

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.

[3] LEE S,ZHANG C,LIU Z,et al. Network analyses identify liver-specific targets for treating liver diseases[J]. Mol Syst Biol,2017,13(8):938.

[4] WANG X,LIAO X,YANG C,et al. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy[J]. Oncol Rep,2019,41(3):1586-1602.

[5] LI J,KE W,ZHOU Q,et al. Tumour necrosis factor-αpromotes liver ischaemia-reperfusion injury through the PGC-1α/Mfn2 pathway[J]. J Cell Mol Med,2014,18(9):1863-1873.

[6] MANCINI G,PIRRUCCIO K,YANG X,et al. Mitofusin 2 in mature adipocytes controls adiposity and body weight[J]. Cell Rep,2019,27(2):648.

[7] HERNNDEZ-ALVAREZ MI,SEBASTIN D,VIVES S,et al.Deficient endoplasmic reticulum-mitochondrial phosphatidylserine transfer causes liver disease[J]. Cell,2019,177(4):881-895.

[8] WU Y,ZHOU D,XU X,et al. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma[J]. World J Surg Oncol,2016,14(1):179.

[9] CAI M,XU L,SHEN L,et al. Expression of long-chain noncoding RNA FOXN3-AS2 in hepatocellular carcinoma and its effect on proliferation and invasion of hepatoma cells[J]. Chin J Clin Pharmacol Ther,2018,23(11):1246-1251.(in Chinese)蔡民，许浏，沈兰，等．长链非编码RNA FOXN3-AS2在肝癌中的表达及其对肝癌细胞增殖和侵袭的影响[J]．中国临床药理学与治疗学，2018,23(11):1246-1251.

[10] LIU JZ,HU GJ,SHI LL,et al. Notch signaling pathway involved in invasion and migration of liver cancer cells[J]. Clin J Med Offic,2017,45(11):1159-1161.(in Chinese)刘建中，胡广军，时玲玲，等．Notch信号通路参与肝癌细胞侵袭迁移临床机制研究[J]．临床军医杂志，2017,45(11):1159-1161.

[11] WANG C,GONG J,WU H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease[J]. Biomed Rep,2017,7(2):95-104.

[12] ADAM M,HEIKELH,SOBOLEWSKI C,et al. Hydroxysteroid(17β)dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice[J]. FASEB J,2018,32(6):3434-3447.

[13] CHEN J,ZHUO JY,YANG F,et al. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2018,17(3):220-226.

[14] XU G,YANG F,DING CL,et al. Small nucleolar RNA 113-1suppresses tumorigenesis in hepatocellular carcinoma[J].Mol Cancer,2014,13:216.

[15] YU CB,ZHU LY,WANG YG,et al. Systemic transcriptome analysis of hepatocellular carcinoma[J]. Tumour Biol,2016,37(10):13323-13331.

[16] SUN B,KARIN M. Obesity,inflammation,and liver cancer[J]. J Hepatol,2012,56(3):704-713.

[17] CHENG X,ZHOU D,WEI J,et al. Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-expressed mitofusin-2 gene in human colorectal cancer cell lines[J]. Neoplasma,2013,60(6):620-626.

[18] WANG W,LU J,ZHU F,et al. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells[J]. Med Oncol,2012,29(1):70-76.

[19] SONG J,ZHAO W,LU C,et al. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK-Mfn2 signaling pathway[J]. Cancer Cell Int,2019,19:60.

Relative Articles

[1]	Yao Xin, Zhou Hao, Tang ShanHong, Huang Shan, Chen XueLing, Qin JianPing. Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2020, 36(9): 1970-1974. doi: 10.3969/j.issn.1001-5256.2020.09.012
[2]	Huang Shan, Zhou Hao, Chen XueLing, Yao Xin, Tang ShanHong, Yang GuoDong, Qin JianPing. Effect of transjugular intrahepatic portosystemic shunt on the liver and the heart[J]. Journal of Clinical Hepatology, 2020, 36(4): 904-907. doi: 10.3969/j.issn.1001-5256.2020.04.043
[3]	Li Jing, Jiang Yong, Zhang Xu. Efficacy of transjugular intrahepatic portosystemic shunt versus endoscopic cyanoacrylate injection in treatment of gastric variceal bleeding: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(2): 349-353. doi: 10.3969/j.issn.1001-5256.2019.02.021
[4]	Zou SongLong, Xu Ying. Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(1): 201-204. doi: 10.3969/j.issn.1001-5256.2019.01.044
[5]	Yao Xin, Zhou Hao, Tang ShanHong, Xie Min, Huang Shan, Qin JianPing. Stent dysfunction after transjugular intrahepatic portosystemic shunt: Causes and countermeasures[J]. Journal of Clinical Hepatology, 2019, 35(5): 1052-1056. doi: 10.3969/j.issn.1001-5256.2019.05.023
[6]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. Journal of Clinical Hepatology, 2019, 35(12): 2694-2699. doi: 10.3969/j.issn.1001-5256.2019.12.010
[7]	He ChuangYe, Chen Hui, Lyu Yong, Xia DongDong, Yu TianLei, Yuan XuLong, Li Kai, Wang ZhengYu, Niu Jing, Bai Wei, Guo WenGang, Tie Jun, Yin ZhanXin, Han GuoHong. Safety and efficacy of flow-reducing stent in treatment of recurrent or persistent hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(8): 1719-1722. doi: 10.3969/j.issn.1001-5256.2019.08.014
[8]	Wang Zhong, Liu FuQuan. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(12): 2824-2827. doi: 10.3969/j.issn.1001-5256.2019.12.040
[9]	Ding ZhiFeng, Yin ShiWu, Zhang GuoBing, Wang MingQuan, Pan ShengQuan. Clinical effect of Viatorr stent versus double-stent technique in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(3): 579-582. doi: 10.3969/j.issn.1001-5256.2018.03.026
[10]	Ding ZhiFeng, Yin ShiWu. Application of Viatorr covered stent in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(5): 1107-1110. doi: 10.3969/j.issn.1001-5256.2018.05.039
[11]	Zhang XinTong, Qi XingShun, Luo JianJun, Guo XiaoZhong. An excerpt of consensus conference on TIPS management: techniques, indications, contraindications (Italy, 2016)[J]. Journal of Clinical Hepatology, 2017, 33(3): 428-431. doi: 10.3969/j.issn.1001-5256.2017.03.005
[12]	Interventional Group, Chinese Society of Radiology, Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2017, 33(7): 1218-1228. doi: 10.3969/j.issn.1001-5256.2017.07.004
[13]	Tuo Lin, Tang ShanHong, Zeng WeiZheng, Wu XiaoLing. Treatment and prevention strategies to complications of transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 354-357. doi: 10.3969/j.issn.1001-5256.2016.02.034
[14]	Zhai YaNan, Li Lei, Yin Liang, Guo QiHong, Lei JunQiang, Guo ShunLin, Zhang ChunYu, Wang HaiJun, Wen XiaoXiao. Role of dual-source CT low-dose whole liver perfusion imaging in evaluating liver blood perfusion after transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(10): 1894-1899. doi: 10.3969/j.issn.1001-5256.2016.10.014
[15]	Niu Meng, Sun Jun, Xu Ke, Zhong HongShan. Retrospects and prospects of transjugular intrahepatic portosystemic shunt in China[J]. Journal of Clinical Hepatology, 2016, 32(2): 230-233. doi: 10.3969/j.issn.1001-5256.2016.02.005
[16]	Ren ShuYao, Chen Hui, Lu: Yong, Wang ZhengYu, Niu Jing, Yin ZhanXin, He ChuangYe, Guo WenGang, Han GuoHong. Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment[J]. Journal of Clinical Hepatology, 2016, 32(6): 1112-1117. doi: 10.3969/j.issn.1001-5256.2016.06.018
[17]	Xu Lu, Xiao Xue, Liu JingQi, Wang Jing, Zhou JingJing, Jiang ChunMeng. Influence of covered stent versus bare stent on long-term efficacy of transjugular intrahepatic portosystemic shunt: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1900-1905. doi: 10.3969/j.issn.1001-5256.2016.10.015
[18]	Wang TingTing, Zhang Feng, ZhuGe YuZheng. Research progress in TIPS shunt dysfunction and recanalization[J]. Journal of Clinical Hepatology, 2015, 31(11): 1921-1923. doi: 10.3969/j.issn.1001-5256.2015.11.041
[19]	Zheng LuanLuan, Han GuoHong, Fan DaiMing. Role of transjugular intrahepatic portosystemic shunt in prevention and treatment of variceal bleeding in liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 687-690. doi: 10.3969/j.issn.1001-5256.2014.07.031
[20]	Tang ShanHong, Qin JianPing, Jiang MingDe, Ceng WeiZheng, Yao Xin, He QianWen, Tang Wen, Gu Ming. Clinical effect and safety of TIPS in treatment of portal hypertension due to alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(2): 145-148. doi: 10.3969/j.issn.1001-5256.2014.02.012

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	张欣，徐怡琼，罗艳，张富军. 吲哚菁绿清除实验的临床应用及研究进展. 上海医学. 2024(05): 314-317 .
2.	李文惠. 分析乳果糖预防肝硬化患者上消化道出血后诱发肝性脑病的疗效. 医学食疗与健康. 2022(13): 29-31+42 .
3.	吴敏，张丽霞. 肠道微生物代谢组学检测在疾病诊疗中的研究进展. 淮海医药. 2022(04): 434-437 .
4.	柴晓哲，朱霞峰，王少峰，骆成林. 白蛋白-胆红素评分联合血氨检测对原发性肝癌切除术后并发肝性脑病的预测价值. 肝脏. 2022(09): 994-998 .
5.	冯其柱，王思雨，张超. 吲哚菁绿荧光显影在困难胆囊腹腔镜胆囊切除术中的应用价值. 临床肝胆病杂志. 2022(11): 2537-2541 . 本站查看
6.	史俪璐，徐慧，陈慧. 双歧杆菌三联活菌胶囊联合乳果糖对经颈静脉肝内门体分流术后肝性脑病的预防效果分析. 中国医学前沿杂志(电子版). 2021(05): 79-83 .
7.	袁巍，李龙鹤，韩晓玉，刘俊，李波，武金才. TIPS术后发生肝性脑病的临床预测模型建立与效能分析. 现代消化及介入诊疗. 2021(07): 874-877 .
8.	路志伟. MRI+多层螺旋CT对于肝性脑病患者诊断准确率的影响分析. 中国实用医药. 2021(26): 21-23 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1320) PDF downloads(224)

Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

DOI: 10.3969/j.issn.1001-5256.2019.12.019